ANALYTICAL METHOD VALIDATION, PHARMACOKINETICS AND BIOEQUIVALENCE STUDY OF DIMETHYL FUMARATE IN HEALTHY IRANIAN VOLUNTEERS
Keywords:Bioequivalent, Pharmacokinetics, Multiple sclerosis, Dimethyl fumarate, LC-MS/MS
Objective: Pharmacokinetic evaluation of Dimethyl Fumarate (DMF) in the Iranian population wasn’t studied. So, the aim of this research is the validation of the analytical method and evaluation of the pharmacokinetic properties and bioequivalence of the generic form of this drug versus the reference product.
Methods: 2 single-dose, test, and reference DMF products were orally administered to 24 healthy volunteers. The washout period was 28 d between the treatments. Monomethyl fumarate as the metabolite of DMF was analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and the method was validated. Also, the pharmacokinetic parameters were calculated for bioequivalence evaluation.
Results: The analytical method was validated and linear over the range of 31.25-4000 ng/ml (R2= 0.997). In addition, the method was precise and accurate in the low, medium, and high concentrations. The results indicated that the 2 products had similar pharmacokinetics. Further, the 90% CI of the mean ratios of the test versus the reference products of the log-transformed area under the concentration-time curve over 10 h (0.99 to 1.02) and peak concentration (0.98 to 1.03) were within the acceptable range of 0.8 to 1.25 and the generic product of DMF could be similar to that of the reference product.
Conclusion: The applied analytical method is selective, accurate, precise, and repeatable for the analysis of monomethyl fumarate (MMF) in plasma. Also, the bioequivalence study showed no significant difference between the pharmacokinetic parameters of these 2 products. So, the DMF test product can be claimed to be bioequivalent with the reference product.
Rouini MR, Dibaei M, Ghasemian E. Pharmacokinetics and bioequivalence studies of teriflunomide in healthy Iranian volunteers. Clin Pharmacol Drug Dev 2020;9:341-5.
Goldenberg MM. Multiple sclerosis review. PT 2012;37:175-84.
Burness CB, Deeks ED. Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis. CNS Drugs 2014;28:373-87.
Ingwersen J, Aktas O, Hartung HP. Advances in and algorithms for the treatment of relapsing-remitting multiple sclerosis. Neurotherapeutics 2016;13:47-57.
Carlstrom KE, Ewing E, Granqvist M, Gyllenberg A, Aeinehband S, Enoksson SL, et al. Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes. Nat Commun 2019;10:3081.
Foroughipour M, Gazeran S. Effectiveness and side effects of dimethyl fumarate in multiple sclerosis after 12 mo of follow up: an Iranian clinical trial. Iran J Neurol 2019;18:154-8.
Mills EA, Ogrodnik MA, Plave A, Mao Draayer Y. Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis. Front Neurol 2018;9:5.
Venci JV, Gandhi MA. Dimethyl fumarate (Tecfidera) a new oral agent for multiple sclerosis. Ann Pharmacother 2013;47:1697-702.
Fox RJ, Kita M, Cohan SL, Henson LJ, Zambrano J, Scannevin RH, et al. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Curr Med Res Opin 2014;30:251-62.
Cho H, Hartsock MJ, Xu Z, He M, Duh EJ. Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion. J Neuroinflammation 2015;12:239.
TECFIDERA™ (dimethyl fumarate) delayed-release capsules, for oral use, FDA approved labeling text; 2013.
Sheikh SI, Nestorov I, Russell H, O'Gorman J, Huang R, Milne GL, et al. Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. Clin Ther 2013;35:1582-94. e9.
Dubey D, Kieseier BC, Hartung HP, Hemmer B, Warnke C, Menge T, et al. Dimethyl fumarate in relapsing–remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Rev Neurother 2015;15:339-46.
Tecfidera 240 mg gastro-resistant hard capsules: Annex I: summary of product characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/tecfidera-epar-product-information_en.pdf. [Last accessed on 02 May 2021].
Thomas RH, Wakefield RA. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis. Am J Health Syst Pharm 2015;72:25-38.
Bioanalytical Method Validation Guidance for Industry. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), USA; 2018. Available from: https://www.fda.gov/ files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. [Last accessed on 02 May 2021]
Guidance for Industry Q2B Validation of Analytical Procedures: Methodology. Geneva; 1996. Available from: https:// www.fda.gov/media/71725/download.[Last accessed on 02 May 2021].
Tijare LK, Rangari NT, Mahajan UN. A review on bioanalytical method development and validation. Asian J Pharm Clin Res 2016;9 (Suppl 3):6-10.
Wenkui L, Ying HL, Austin C, Shaolin Z, Weng N. Simultaneous determination of norethindrone and Ethinyl estradiol in human plasma by high-performance liquid chromatography with tandem mass spectrometry-experience on developing a highly selective method using derivatization reagent for enhancing sensitivity. J Chromatogr B: Anal Technol Biomed Life Sci 2005;825:223-32.
Adluri P, Kumar YS. Development and validation of sensitive LC-ESI-MS/MS method for the simultaneous estimation of dapagliflozine and saxagliptin in human plasma. Int J Pharm Pharm Sci 2019;11:55-9.
Harahap Y, Malia CD, Sunarish. Pharmacokinetic profile of metformin hydrochloride in dried blood spot of healthy subjects using high performance liquid chromatography-photodiode assay. Int J Appl Pharm 2018;10:354-7.
Design and Analysis of Bioavailability and Bioequivalence Studies. 2nd ed. Revised and Expanded. Shein-Chung Chow and Jen-Pei Liu; 2000.
Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products–General Considerations. U. S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER); 2003.
Drug control division, Food and drug administration, Ministry of Public Health, Thailand. Guideline for the conduct of bioavailability and bioequivalence studies; 2009.
Lategan TW, Wang L, Sprague TN, Rousseau FS. Pharmacokinetics and bioavailability of monomethyl fumarate following a single oral dose of bafertam™ (Monomethyl Fumarate) or Tecfdera® (Dimethyl Fumarate). CNS Drugs 2021;35:567–74.
How to Cite
Copyright (c) 2021 GHASEMIAN ELHAM, SADRAI SIMA, SHOKRI JAVAD, SAYADI SHAHRAM
This work is licensed under a Creative Commons Attribution 4.0 International License.